mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
David CasadevallAnna Hernández-PratSara García-AlonsoOriol Arpí-LluciàSilvia MenéndezMengjuan QinCristina GuardiaBeatriz MoranchoFrancisco Javier Sánchez-MartínSandra ZazoElena GavilánMohammad A SabbaghiPilar ErolesJuan Miguel CejalvoAna LluchFederico RojoAtanasio PandiellaAna RoviraJoan AlbanellPublished in: Molecular cancer research : MCR (2022)
Inhibition of mTOR increases the antitumor activity of T-DM1, supporting that the combination of mTOR inhibitors and antibody-drug conjugates warrants clinical evaluation in patients with HER2-positive breast cancer.